This market has settled: RESOLVED
Settled on April 4, 2026
Will there be at least 2200 measles cases in the U.S. by April 30, 2026?
Will there be at least 2200 measles cases in the U.S. by April 30, 2026? Odds: 5.5% YES on Polymarket. See live prices and trade this market.
Measles Cases Market Analysis
Current Odds
| Platform | Yes | No | Volume | Trade |
|---|---|---|---|---|
| Polymarket | 5.5% | 94.5% | $10K | Trade on Polymarket |
Market Analysis
The 5.5% YES odds reflect very low market confidence in a measles outbreak reaching 2,200 cases by April 2026, but this probability may underestimate genuine public health risks given current vaccination trends and political dynamics around immunization policy. The U.S. reported 271 measles cases in 2024 and 507 in 2023, meaning traders are betting against an approximately 4-5x surge in cases over the next 18 months—a significant escalation that would require substantial changes to vaccination coverage or disease spread patterns.
The bull case rests on declining immunization rates driven by anti-vaccine sentiment gaining political legitimacy. Several states have already expanded religious and philosophical exemptions to vaccination requirements; if this accelerates following the 2024 election cycle and extends into school policy changes for the 2025-2026 academic year, measles could spread rapidly through undervaccinated communities. The virus’s R0 (reproduction number) of 12-18 means pockets of low immunity create exponential growth potential. Additionally, any disruption to routine childhood vaccination programs during the period (supply chain issues, clinic closures, or policy changes) could compound susceptibility. Watch for state legislative actions on vaccine exemptions through spring 2025 and any CDC reporting showing declining MMR vaccination coverage below 90% in specific regions.
The bear case hinges on measles remaining endemic rather than epidemic in the U.S. Current baseline immunity remains high enough to contain isolated outbreaks; the 2019 outbreak peaked at 1,282 cases despite significant undervaccination in specific communities. Federal immunization programs continue despite political headwinds, and healthcare infrastructure for detecting and isolating measles cases remains functional. The market’s 5.5% pricing assumes public health authorities will maintain containment, a reasonable baseline given historical precedent even during anti-vaccine waves.
Key catalysts include FDA/CDC guidance updates on vaccination campaigns (typically quarterly), state legislative sessions through spring 2025 where exemption bills may advance, and monthly vaccination coverage reports from CDC tracking trends toward April 2026. Any measles cases detected in 2025 should be monitored—they serve as early warnings for spread potential. The market currently prices in extremely low probability, suggesting substantial value may exist if anti-vaccine political momentum continues translating into policy changes affecting school vaccination rates.
Related Markets
- Will Pete Buttigieg win the 2028 Democratic presidential nomination? — 4% YES
- Will the People Power Party (PPP) win the 2026 South Korean local elections? — 5% YES
- Will Amanda Anisimova be the 2026 Women’s Wimbledon Winner? — 6% YES
Frequently Asked Questions
What vaccination coverage threshold would likely trigger a 2,200-case outbreak?
Epidemiological models suggest measles spread significantly accelerates when MMR coverage drops below 85-90% in specific communities; sustained coverage below 80% regionally creates outbreak conditions, but national coverage would need to fall dramatically or geographically concentrate in high-density areas to reach 2,200 cases.
How much have U.S. measles cases grown year-over-year recently, and what would the April 2026 target require?
Cases grew from 271 (2024) to 507 (2023), representing roughly a 2x increase; reaching 2,200 would require maintaining or accelerating that growth trajectory across 2025-2026, which would represent a 4-5x surge from current baseline and would be the largest outbreak since the pre-vaccine era.
Could a single super-spreader event or travel-related cluster drive this outcome?
Unlikely alone—even the largest recent U.S. outbreaks (1,282 cases in 2019, 704 in 2014) occurred during periods of significantly lower vaccination rates; 2,200 cases by April 2026 would require sustained community transmission indicating